市場調查報告書
商品編碼
1419637
精準腫瘤學市場- 按產品類型(診斷{基因測試、基於生物標記的測試}、治療)、癌症類型(乳腺癌、肺癌、結直腸癌、皮膚、前列腺、胃)、最終用戶(醫院、診斷中心)、全球預測2023-2032Precision Oncology Market - By Product Type (Diagnostics {Genetic Tests, Biomarker-based Tests}, Therapeutics), Cancer Type (Breast, Lung, Colorectal, Skin, Prostrate, Stomach), End-user (Hospitals, Diagnostic Centers), Global Forecast 2023-2032 |
在基因組研究不斷進步的推動下,精準腫瘤學市場預計從 2023 年到 2032 年將以 10.6% 的複合CAGR擴張。最近在了解癌症遺傳基礎方面的突破使得能夠精確識別分子變化並推動標靶治療的發展。下一代定序等技術的不斷發展也提供了全面的基因組分析。一些腫瘤學家正在根據個別患者的情況量身定做這些療法,以提供個人化和有針對性的癌症護理。
此外,一些公司正在透過業務發展的合作和收購等策略性努力,將優質的後期精準腫瘤學資產添加到其業務概況中,從而擴大其腫瘤學服務,從而增強行業前景。例如,2022 年 3 月,百時美施貴寶收購了領先的精準腫瘤公司 Turning Point Therapeutics。
整個產業分為產品類型、癌症類型、最終用戶和地區。
根據產品類型,診斷領域的精準腫瘤市場預計 2023 年至 2032 年CAGR為 11.7%。先進的診斷工具和技術,包括下一代定序、分子影像和液體活體組織切片分析,正在促進精準腫瘤學的日益普及。診斷產品不斷發展以提供更高的準確性和效率,從而增強了其在腫瘤學領域的應用。此外,對全面基因組分析、腫瘤特徵和早期癌症檢測以支持個人化治療策略的需求激增,將推動該細分市場的成長。
對於最終用戶而言,到 2032 年,診斷中心的精準腫瘤學產業預計將以 11.4% 的成長率成長。癌症發生率的增加導致對精準和個人化診斷解決方案的需求不斷成長。診斷中心在提供先進的分子分析和基因檢測服務以實現標靶癌症治療方面也發揮關鍵作用。人們越來越認知到使用精準醫學進行更有效的癌症治療所帶來的好處,這將進一步擴大腫瘤學診斷服務的使用。
從地區來看,由於癌症發生率的增加、意識的提高以及基因組研究的快速進步,亞太地區精準腫瘤學市場預計在 2023 年至 2032 年間呈現 11.4% 的成長率。例如,根據 NCBI 估計,印度報告 2022 年癌症發生率為 14,61,427 例。此外,亞太地區的多個政府和醫療機構正在投資精準腫瘤學計劃,進一步促進個人化癌症治療方法。此外,該地區多樣化的患者群體為鼓勵採用精準醫療、加速區域產業擴張提供了寶貴的遺傳見解。
Precision Oncology Market is set to expand at 10.6% CAGR from 2023 and 2032 propelled by the continuous advancements in genomic research. Recent breakthroughs in understanding the genetic basis of cancers is enabling the precise identification of molecular alterations and driving the development of targeted therapies. The ongoing evolution of technologies like next-generation sequencing is also providing comprehensive genomic profiling. Several oncologists are tailoring these therapies based on individual patient profiles to provide personalized and targeted cancer care.
Furthermore, several companies are expanding their oncology services by adding superior, late-stage precision oncology assets to their business profiles through strategic efforts, such as collaborations and acquisitions for business development, augmenting the industry outlook. For instance, in March 2022, Bristol Myers Squibb acquired Turning Point Therapeutics, a leading precision oncology company.
The overall industry is segmented into product type, cancer type, end-user, and region.
Based on product type, the precision oncology market from the diagnostic segment is projected to grow at 11.7% CAGR from 2023-2032. Advanced diagnostic tools and technologies, including next-generation sequencing, molecular imaging, and liquid biopsy assays, are contributing to the increasing adoption of precision oncology. The continuous evolution of diagnostic products for offering higher accuracy and efficiency is enhancing their adoption in oncology settings. Additionally, the surging need to enable comprehensive genomic profiling, tumor characterization, and early cancer detection for supporting personalized treatment strategies will drive the segment growth.
As per end-user, the precision oncology industry from the diagnostic centers is expected to depict 11.4% growth rate through 2032. The increasing number of cancer incidences is resulting in the rising demand for precise and personalized diagnostic solutions. Diagnostic centers also play a pivotal role in offering advanced molecular profiling and genetic testing services for enabling targeted cancer therapies. The rising awareness of the benefits associated with the use of precision medicine for more effective cancer treatments will further amplify the use of diagnostic services in oncology.
Regionally, the Asia Pacific precision oncology market is set to exhibit an 11.4% growth rate between 2023 and 2032 attributed to the increasing cancer incidences, rising awareness, and the rapid advancements in genomic research. For instance, according to NCBI estimates, India reported 14,61,427 incidence cases of cancer in 2022. Moreover, several governments and healthcare institutions in APAC are investing in precision oncology initiatives, further fostering personalized cancer treatment approaches. Additionally, the diverse patient populations in the region is offering valuable genetic insights for encouraging the adoption of precision medicine, accelerating the regional industry expansion.